<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006848</url>
  </required_header>
  <id_info>
    <org_study_id>OSTPDL1</org_study_id>
    <secondary_id>NCI-2016-02036</secondary_id>
    <secondary_id>Pfizer W1211733 (OSTPDL1)</secondary_id>
    <secondary_id>Gateway RESAG</secondary_id>
    <nct_id>NCT03006848</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma</brief_title>
  <official_title>A Phase II Trial of Avelumab, A Fully Human Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gateway for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial seeks to determine if avelumab will be effective in facilitating removal&#xD;
      of all gross tumor in the event of a relapse of osteosarcoma in pediatric patients. Avelumab&#xD;
      will be evaluated using dosing that has previously been determined in adult studies.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        -  To estimate the response rate to 4 cycles of avelumab in patients with recurrent or&#xD;
           progressive osteosarcoma.&#xD;
&#xD;
        -  To estimate the 16-week progression free survival of patients with recurrent or&#xD;
           progressive osteosarcoma after treatment with avelumab.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To describe the toxicities associated with the administration of avelumab in patients&#xD;
           with recurrent or progressive osteosarcoma.&#xD;
&#xD;
        -  To assess the quality of life of patients with recurrent or progressive osteosarcoma&#xD;
           undergoing treatment with avelumab, and to explore relationships between clinical&#xD;
           factors and patient-reported health-related quality of life (HRQOL) outcomes.&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
        -  To explore factors associated with response in patients treated with avelumab after&#xD;
           recurrent or progressive osteosarcoma (e.g. tumor PD-L1 expression).&#xD;
&#xD;
        -  To measure parameters of immune activation including subsets of peripheral blood&#xD;
           mononuclear cells (PBMCs) and serum markers of immune activation.&#xD;
&#xD;
        -  To evaluate the role of T-cells in immune checkpoint blockade via measures of cell&#xD;
           proliferation, co-inhibitory receptor expression on CD8 T cells, T cell repertoire, and&#xD;
           epigenetic programming.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 study using a traditional Simon two-stage design. Patients 12 years or&#xD;
      greater with recurrent/refractory osteosarcoma will be administered avelumab at a dose of 10&#xD;
      mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting&#xD;
      28 days.&#xD;
&#xD;
      Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26&#xD;
      cycles. Progression free survival and response to therapy after 4 cycles of treatment will be&#xD;
      assessed. In addition, the toxicity profile of avelumab in this population will be closely&#xD;
      monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Actual">March 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>At the end of 4 cycles of avelumab (approximately 4 months)</time_frame>
    <description>The study is designed by treating RECIST response [complete response + partial response (CR+PR)] after 4-cycle treatment of avelumab and the 16-week progression-free survival (PFS) as dual binary endpoints. Patients who fail to be evaluated at the end of the 4-cycle will be counted as failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>At the end of 4 cycles of avelumab (approximately 4 months)</time_frame>
    <description>The study is designed by treating RECIST response [complete response + partial response (CR+PR)] after 4-cycle treatment of avelumab and the 16-week progression-free survival (PFS) as dual binary endpoints. Patients who fail to be evaluated at the end of the 4-cycle will be counted as failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Toxicities</measure>
    <time_frame>At the end of treatment (up to 2 years after enrollment of last participant)</time_frame>
    <description>Target toxicities for avelumab treatment are defined as any grade 3-5 dyspnea, infusion-related reactions, or immune related adverse events at least possibly attributable to the agent observed anytime during the 26-cycle treatment period that a patient is on study (including the period between off treatment and off study).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Factors Associated With Response</measure>
    <time_frame>Following completion of therapy for last participant (up to 2 years after enrollment)</time_frame>
    <description>Logistic regression analysis will be conducted to explore factors which may associate with response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Parameters of Immune Activation</measure>
    <time_frame>Baseline prior to start of therapy and following 2 cycles of therapy (up to 8 weeks after last enrollment)</time_frame>
    <description>Descriptive statistics will be provided.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Cell Proliferation</measure>
    <time_frame>Baseline prior to start of therapy and after completion of therapy (approximately 2 years after last participant enrollment).</time_frame>
    <description>Descriptive statistics will be provided.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Co-inhibitory Receptor Expression on CD8 T Cells</measure>
    <time_frame>Baseline prior to start of therapy and after completion of therapy (approximately 2 years after last participant enrollment).</time_frame>
    <description>Descriptive statistics will be provided.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>From baseline prior to start of treatment through the end of avelumab therapy (up to approximately 2 years)</time_frame>
    <description>Participants will self-report their quality of life through PROMIS questionnaires, either the Pediatric Profile (ages 8 to 17 years) or the Adult Profile (age 18 years or older). The change in age-normed T-scores will be reported. Mixed effect models will be performed to assess changes in quality of life over time.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants with recurrent/refractory osteosarcoma who consent to the study.&#xD;
Interventions: Avelumab and quality of life questionnaires.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.</description>
    <arm_group_label>Avelumab</arm_group_label>
    <other_name>MSB0010718C</other_name>
    <other_name>anti-PD-L1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>To assess quality of life, patients will complete questionnaires at four time points.</description>
    <arm_group_label>Avelumab</arm_group_label>
    <other_name>PROMIS Pediatric Profile</other_name>
    <other_name>PROMIS Adult Profile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be &gt; 12 years of age but &lt; 50 years of age at the time of enrollment.&#xD;
&#xD;
          -  Patients must have histologic verification of osteosarcoma at initial diagnosis or&#xD;
             relapse.&#xD;
&#xD;
          -  Patients must have had evidence of having relapsed, progressed or become refractory to&#xD;
             conventional therapy.&#xD;
&#xD;
          -  Patients must have measurable disease, documented by clinical, radiographic or&#xD;
             histologic criteria. Disease must be bi-dimensionally measurable by computed&#xD;
             tomography (CT) or magnetic resonance imaging (MRI).&#xD;
&#xD;
          -  Patients must have a performance status of ≥ 50 using the Karnofsky scale for patients&#xD;
             &gt; 16 years of age and the Lansky scale for patients ≤ 16 years of age.&#xD;
&#xD;
          -  Patients must have a life expectancy of ≥ 6 weeks.&#xD;
&#xD;
          -  Patients must have fully recovered from the acute toxic effects of all prior&#xD;
             chemotherapy, immunotherapy, or radiotherapy prior to entering this study.&#xD;
&#xD;
               1. Myelosuppressive chemotherapy: must not have received within 3 weeks of entry&#xD;
                  onto this study.&#xD;
&#xD;
               2. Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy&#xD;
                  with a biologic agent.&#xD;
&#xD;
               3. Immunotherapies: at least 42 days must have elapsed since a prior therapy that&#xD;
                  included a monoclonal antibody or any other type of immunotherapy (e.g. chimeric&#xD;
                  antigen receptor (CAR) T cell therapy).&#xD;
&#xD;
               4. Radiation therapy (RT): ≥ 2 weeks for local palliative RT (small port); ≥ 6&#xD;
                  months must have elapsed if prior craniospinal RT or if ≥ 50% radiation of the&#xD;
                  pelvis; ≥ 6 weeks must have elapsed if other substantial bone marrow (BM)&#xD;
                  radiation.&#xD;
&#xD;
          -  Organ Function Requirements:&#xD;
&#xD;
               1. Adequate bone marrow function defined as:&#xD;
&#xD;
                    -  Peripheral absolute neutrophil count (ANC) ≥ 1500/mm3&#xD;
&#xD;
                    -  Platelet count ≥ 100,000/mm3 (transfusion independent)&#xD;
&#xD;
                    -  Hemoglobin ≥ 9.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
               2. Adequate renal function defined as:&#xD;
&#xD;
                    -  Creatinine clearance or radioisotope GFR ≥70 mL/min/1.73m2 OR&#xD;
&#xD;
                    -  Serum creatinine based on age/gender as follows: (threshold creatinine&#xD;
                       values were derived from the Schwartz formula for estimating GFR).&#xD;
&#xD;
                         -  Age is: 12 to &lt;13 years, then maximum creatinine is 1.2 mg/DL for male&#xD;
                            and female.&#xD;
&#xD;
                         -  Age is: 13 to &lt;16 years, then maximum creatinine is 1.5 mg/DL for male&#xD;
                            and 1.4 mg/DL for female.&#xD;
&#xD;
                         -  Age is: ≥16 years, then maximum creatinine is 1.7 mg/DL for male and&#xD;
                            1.4 mg/DL for female.&#xD;
&#xD;
               3. Adequate liver function defined as:&#xD;
&#xD;
                    -  Total Bilirubin ≤ 1.5x the institutional upper limit of normal (IULN) for&#xD;
                       age&#xD;
&#xD;
                    -  ALT (SGPT) and AST (SGOT) &lt; 2.5 x IULN for age (or &lt; 5 x IULN for patients&#xD;
                       with documented metastatic disease to the liver)&#xD;
&#xD;
                    -  Serum albumin &gt; 2 g/dL&#xD;
&#xD;
               4. Serum lipase ≤ upper limit of normal (IULN).&#xD;
&#xD;
               5. Patients must have documented pulse oximetry ≥ 92% on room air.&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test within 7 days of enrollment.&#xD;
&#xD;
          -  Male or female patients who are sexually active and of reproductive potential must&#xD;
             agree to use an effective contraceptive method throughout the study and for at least&#xD;
             60 days after last avelumab treatment administration. Abstinence is an acceptable form&#xD;
             of contraception.&#xD;
&#xD;
          -  Patients must not currently be using other investigational agents.&#xD;
&#xD;
          -  Patients must not currently be using other anti-cancer agent.&#xD;
&#xD;
          -  Patients must be able to comply with the safety monitoring of the study in the opinion&#xD;
             of the investigator.&#xD;
&#xD;
          -  Written, informed consent and assent following Institutional Review Board, NCI, FDA&#xD;
             and OHRP guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system (CNS) metastases.&#xD;
&#xD;
          -  Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal,&#xD;
             inhaled, topical steroids, or local steroid injection (e.g., intra-articular&#xD;
             injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone&#xD;
             or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT&#xD;
             scan premedication).&#xD;
&#xD;
          -  Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory&#xD;
             agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid&#xD;
             diseases not requiring immunosuppressive treatment are eligible.&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Known history of testing positive for HIV or known acquired immunodeficiency syndrome.&#xD;
&#xD;
          -  Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive&#xD;
             HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).&#xD;
&#xD;
          -  Patient who has received vaccination within 4 weeks of the first dose of avelumab and&#xD;
             while on trials is prohibited except for administration of inactivated vaccines.&#xD;
&#xD;
          -  Known prior severe hypersensitivity to investigational product or any component in its&#xD;
             formulations, including known severe hypersensitivity reactions to monoclonal&#xD;
             antibodies (NCI CTCAE v4.03 Grade ≥ 3).&#xD;
&#xD;
          -  Clinically significant (i.e., active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months&#xD;
             prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart&#xD;
             Association Classification Class II, see Appendix II), or serious cardiac arrhythmia&#xD;
             requiring medication.&#xD;
&#xD;
          -  Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade &gt; 1); however,&#xD;
             alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety&#xD;
             risk based on investigator's judgment are acceptable&#xD;
&#xD;
          -  Other severe acute or chronic medical conditions including colitis, inflammatory bowel&#xD;
             disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent&#xD;
             (within the past year) or active suicidal ideation or behavior; or laboratory&#xD;
             abnormalities that may increase the risk associated with study participation or study&#xD;
             treatment administration or may interfere with the interpretation of study results&#xD;
             and, in the judgment of the investigator, would make the patient inappropriate for&#xD;
             entry into this study.&#xD;
&#xD;
          -  Patients with active diarrhea &gt; CTCAE v4.03 Grade 2.&#xD;
&#xD;
          -  Patients who have previously received a prior organ transplantation, including&#xD;
             allogeneic stem cell transplantation.&#xD;
&#xD;
          -  Female patients who are pregnant or actively breastfeeding.&#xD;
&#xD;
          -  Patients who have previously received anti-PD1 or anti-PD-L1 therapy. Patients who&#xD;
             have previously received anti-CTLA-4 therapy (e.g. ipilimumab) are eligible for study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W. Bishop, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <results_first_submitted>July 21, 2021</results_first_submitted>
  <results_first_submitted_qc>August 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2021</results_first_posted>
  <disposition_first_submitted>March 4, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 16, 2021</disposition_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteosarcoma</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03006848/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 19 patients were enrolled on the study from February 2017 to April 2021</recruitment_details>
      <pre_assignment_details>18 out of 19 enrolled patients received treatment. The patient who did not receive treatment was found to be ineligible and thus was a screen failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Avelumab</title>
          <description>All participants with recurrent/refractory osteosarcoma who consent to the study.&#xD;
Interventions: Avelumab and quality of life questionnaires.&#xD;
Avelumab: Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.&#xD;
Questionnaires: To assess quality of life, patients will complete questionnaires at four time points.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Avelumab</title>
          <description>All participants with recurrent/refractory osteosarcoma who consent to the study.&#xD;
Interventions: Avelumab and quality of life questionnaires.&#xD;
Avelumab: Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.&#xD;
Questionnaires: To assess quality of life, patients will complete questionnaires at four time points.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>years</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Declined Respond</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <title>St. Jude Children's Research Hospital</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Memorial Sloan-Kettering Cancer Center</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Children's Hospital of Los Angeles</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Texas Children's Research Hospital</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Status at time of enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Recurrent Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>The study is designed by treating RECIST response [complete response + partial response (CR+PR)] after 4-cycle treatment of avelumab and the 16-week progression-free survival (PFS) as dual binary endpoints. Patients who fail to be evaluated at the end of the 4-cycle will be counted as failure.</description>
        <time_frame>At the end of 4 cycles of avelumab (approximately 4 months)</time_frame>
        <population>RECIST response [complete response + partial response (CR+PR)]</population>
        <group_list>
          <group group_id="O1">
            <title>Avelumab</title>
            <description>All participants with recurrent/refractory osteosarcoma who consent to the study.&#xD;
Interventions: Avelumab and quality of life questionnaires.&#xD;
Avelumab: Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.&#xD;
Questionnaires: To assess quality of life, patients will complete questionnaires at four time points.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>The study is designed by treating RECIST response [complete response + partial response (CR+PR)] after 4-cycle treatment of avelumab and the 16-week progression-free survival (PFS) as dual binary endpoints. Patients who fail to be evaluated at the end of the 4-cycle will be counted as failure.</description>
          <population>RECIST response [complete response + partial response (CR+PR)]</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>The study is designed by treating RECIST response [complete response + partial response (CR+PR)] after 4-cycle treatment of avelumab and the 16-week progression-free survival (PFS) as dual binary endpoints. Patients who fail to be evaluated at the end of the 4-cycle will be counted as failure.</description>
        <time_frame>At the end of 4 cycles of avelumab (approximately 4 months)</time_frame>
        <population>Of the 18 eligible patients who received treatment, 17 patients had disease progression while on study and one patient died off study.</population>
        <group_list>
          <group group_id="O1">
            <title>Progression-free Survival</title>
            <description>The study is designed by treating RECIST response [complete response + partial response (CR+PR)] after 4-cycle treatment of avelumab and the 16-week progression-free survival (PFS) as dual binary endpoints. Patients who fail to be evaluated at the end of the 4-cycle will be counted as failure.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>The study is designed by treating RECIST response [complete response + partial response (CR+PR)] after 4-cycle treatment of avelumab and the 16-week progression-free survival (PFS) as dual binary endpoints. Patients who fail to be evaluated at the end of the 4-cycle will be counted as failure.</description>
          <population>Of the 18 eligible patients who received treatment, 17 patients had disease progression while on study and one patient died off study.</population>
          <units>percentage of weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="6.7" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Toxicities</title>
        <description>Target toxicities for avelumab treatment are defined as any grade 3-5 dyspnea, infusion-related reactions, or immune related adverse events at least possibly attributable to the agent observed anytime during the 26-cycle treatment period that a patient is on study (including the period between off treatment and off study).</description>
        <time_frame>At the end of treatment (up to 2 years after enrollment of last participant)</time_frame>
        <population>[Not Specified]</population>
        <group_list>
          <group group_id="O1">
            <title>Target Toxicities</title>
            <description>Target toxicities for avelumab treatment are defined as any grade 3-5 dyspnea, infusion-related reactions, or immune related adverse events at least possibly attributable to the agent observed anytime during the 26-cycle treatment period that a patient is on study (including the period between off treatment and off study).</description>
          </group>
        </group_list>
        <measure>
          <title>Target Toxicities</title>
          <description>Target toxicities for avelumab treatment are defined as any grade 3-5 dyspnea, infusion-related reactions, or immune related adverse events at least possibly attributable to the agent observed anytime during the 26-cycle treatment period that a patient is on study (including the period between off treatment and off study).</description>
          <population>[Not Specified]</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Factors Associated With Response</title>
        <description>Logistic regression analysis will be conducted to explore factors which may associate with response.</description>
        <time_frame>Following completion of therapy for last participant (up to 2 years after enrollment)</time_frame>
        <population>[Not Specified]</population>
        <group_list>
          <group group_id="O1">
            <title>Factors Associated With Response</title>
            <description>Logistic regression analysis will be conducted to explore factors which may associate with response.</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Associated With Response</title>
          <description>Logistic regression analysis will be conducted to explore factors which may associate with response.</description>
          <population>[Not Specified]</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Parameters of Immune Activation</title>
        <description>Descriptive statistics will be provided.</description>
        <time_frame>Baseline prior to start of therapy and following 2 cycles of therapy (up to 8 weeks after last enrollment)</time_frame>
        <population>[Not Specified]</population>
        <group_list>
          <group group_id="O1">
            <title>Change in Parameters of Immune Activation</title>
            <description>Descriptive statistics will be provided.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Parameters of Immune Activation</title>
          <description>Descriptive statistics will be provided.</description>
          <population>[Not Specified]</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Cell Proliferation</title>
        <description>Descriptive statistics will be provided.</description>
        <time_frame>Baseline prior to start of therapy and after completion of therapy (approximately 2 years after last participant enrollment).</time_frame>
        <population>[Not Specified]</population>
        <group_list>
          <group group_id="O1">
            <title>Change in Cell Proliferation</title>
            <description>Descriptive statistics will be provided.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cell Proliferation</title>
          <description>Descriptive statistics will be provided.</description>
          <population>[Not Specified]</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Co-inhibitory Receptor Expression on CD8 T Cells</title>
        <description>Descriptive statistics will be provided.</description>
        <time_frame>Baseline prior to start of therapy and after completion of therapy (approximately 2 years after last participant enrollment).</time_frame>
        <population>[Not Specified]</population>
        <group_list>
          <group group_id="O1">
            <title>Change in Co-inhibitory Receptor Expression on CD8 T Cells</title>
            <description>Descriptive statistics will be provided.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Co-inhibitory Receptor Expression on CD8 T Cells</title>
          <description>Descriptive statistics will be provided.</description>
          <population>[Not Specified]</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Quality of Life</title>
        <description>Participants will self-report their quality of life through PROMIS questionnaires, either the Pediatric Profile (ages 8 to 17 years) or the Adult Profile (age 18 years or older). The change in age-normed T-scores will be reported. Mixed effect models will be performed to assess changes in quality of life over time.</description>
        <time_frame>From baseline prior to start of treatment through the end of avelumab therapy (up to approximately 2 years)</time_frame>
        <population>[Not Specified]</population>
        <group_list>
          <group group_id="O1">
            <title>Change in Quality of Life</title>
            <description>Participants will self-report their quality of life through PROMIS questionnaires, either the Pediatric Profile (ages 8 to 17 years) or the Adult Profile (age 18 years or older). The change in age-normed T-scores will be reported. Mixed effect models will be performed to assess changes in quality of life over time.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life</title>
          <description>Participants will self-report their quality of life through PROMIS questionnaires, either the Pediatric Profile (ages 8 to 17 years) or the Adult Profile (age 18 years or older). The change in age-normed T-scores will be reported. Mixed effect models will be performed to assess changes in quality of life over time.</description>
          <population>[Not Specified]</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Acute adverse events were collected from study enrollment up to 4 weeks after completion of chemotherapy/radiation therapy, whichever came last. Long term toxicity was captured at every visit up to 5 years from study enrollment.</time_frame>
      <desc>[Not specified]</desc>
      <group_list>
        <group group_id="E1">
          <title>Avelumab</title>
          <description>[Not specified]</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <description>Pericardial effusion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Abdominal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Aspartate aminotransferase increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Alanine aminotransferase increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Hyponatremia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <description>Neoplasms benign, malignant and unspecified</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Dyspnea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Bronchopulmonary hemorrhage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>Lung infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <description>Thromboembolic event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <description>Anemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <description>Blood and lymphatic system disorders - Other</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <description>Sinus tachycardia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <description>Pericardial tamponade</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <description>Hyperthyroidism</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Diarrhea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Gastritis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Constipation</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Abdominal pain</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Hemorrhoids</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Rectal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Fever</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Pain</description>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Fatigue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Non-cardiac chest pain</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Gait disturbance</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <description>Autoimmune disorder</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>Lung infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>Urinary tract infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <description>Fall</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Alkaline phosphatase increased</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Aspartate aminotransferase increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Alanine aminotransferase increased</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Blood bilirubin increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Hyperglycemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Hypokalemia</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Hyponatremia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <description>Back pain</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Paresthesia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Peripheral sensory neuropathy</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>Proteinuria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Dyspnea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Pleuritic pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Allergic rhinitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Pneumonitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Bronchopulmonary hemorrhage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Cough</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <description>Rash acneiform</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <description>Alopecia</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One patient changed administration schedule for C2D15 in cycle 2 due to family vacation plan. The variance in dates was submitted to IRB and the patient was approved to continue on treatment when returns from the trip.&#xD;
One patient was unable to travel from Puerto Rico due to hurricane devastation. Dose C2D15 skipped in cycle 2.&#xD;
Medications were given one or two day(s) earlier or later than the scheduled date for a few patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Bishop</name_or_title>
      <organization>St Jude Children's Research Hospital</organization>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

